Qilu Pharmaceutical Co Ltd. has entered into a licensing agreement with Alteogen Inc. for Alteogen’s herceptin biosimilar in China. Under the agreement, Qilu Pharma obtained license for co-development and marketing of a biosimilar developed by Alteogen in China. Alteogen will transfer the technology for the drug to Qilu Pharma for China use. The molecule, ALT-L2, is a biosimilar which is used to treat breast and gastric cancers. ALT-L2 is ready to start a Phase III trial in Canada. This agreement enables Qilu Pharma and Alteogen to develop and market herceptin biosimilar in China.